Mallinckrodt PLC (NYSE:MNK) – Stock analysts at Leerink Swann dropped their FY2021 earnings per share (EPS) estimates for shares of Mallinckrodt in a research note issued on Tuesday, November 6th. Leerink Swann analyst A. Fadia now expects that the company will post earnings per share of $3.82 for the year, down from their previous forecast of $3.88. Leerink Swann currently has a “Market Perform” rating and a $27.00 price objective on the stock.

Mallinckrodt (NYSE:MNK) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $2.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.31. The company had revenue of $640.00 million during the quarter, compared to analyst estimates of $634.38 million. Mallinckrodt had a return on equity of 9.60% and a net margin of 65.24%. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.97 EPS.

Several other analysts also recently weighed in on MNK. B. Riley increased their target price on Mallinckrodt from $20.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 24th. Zacks Investment Research upgraded Mallinckrodt from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research note on Monday, August 27th. Wells Fargo & Co restated a “hold” rating on shares of Mallinckrodt in a research report on Wednesday, August 22nd. Canaccord Genuity set a $34.00 price target on shares of Mallinckrodt and gave the stock a “hold” rating in a report on Sunday, August 19th. Finally, Morgan Stanley increased their price objective on Mallinckrodt from $14.00 to $35.00 and gave the company an “equal weight” rating in a report on Friday, August 17th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $32.53.

NYSE:MNK opened at $30.89 on Friday. The company has a current ratio of 2.21, a quick ratio of 2.06 and a debt-to-equity ratio of 0.93. Mallinckrodt has a 1-year low of $11.65 and a 1-year high of $36.65. The firm has a market cap of $2.56 billion, a P/E ratio of 4.12, a price-to-earnings-growth ratio of 0.42 and a beta of 1.71.

A number of hedge funds have recently bought and sold shares of the business. Affinity Investment Advisors LLC purchased a new stake in Mallinckrodt during the 3rd quarter worth approximately $545,000. American International Group Inc. increased its holdings in Mallinckrodt by 1.3% during the 3rd quarter. American International Group Inc. now owns 222,252 shares of the company’s stock worth $6,514,000 after purchasing an additional 2,951 shares during the last quarter. Martingale Asset Management L P increased its holdings in Mallinckrodt by 52.7% during the 3rd quarter. Martingale Asset Management L P now owns 75,456 shares of the company’s stock worth $2,212,000 after purchasing an additional 26,030 shares during the last quarter. Capital Growth Management LP purchased a new stake in Mallinckrodt during the 3rd quarter worth approximately $5,569,000. Finally, PNC Financial Services Group Inc. increased its holdings in Mallinckrodt by 258.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 28,602 shares of the company’s stock worth $839,000 after purchasing an additional 20,622 shares during the last quarter.

Mallinckrodt Company Profile

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Read More: Capital Gains

Earnings History and Estimates for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.